Peptide LexiconAll compounds

FOXO4-DRI: The Mirror-Image Peptide Built to Clear Old Cells in Mice, With No Human Trial on Record

FOXO4-DRI is a 46-amino-acid research peptide made of D-amino acids, designed in 2017 to make senescent cells self-destruct by freeing the protein p53. In mice it restored fur, fitness and kidney markers. No human trial has been registered. This entry covers its design, the mouse results and what is missing.

Research peptideNot approved anywhereNo human trial registered

Caroline S · Published 2026-11-16

Length

46 amino acids, all D-form; molecular weight 5,358.2 (Baar et al. 2017, methods)

Sequence

ltlrkepaseiaqsileaysqngwanrrsggkrppprrrqrrkkrg (lower case = D-amino acids; Baar et al. 2017, Cell)

Origin

Designed in the de Keizer laboratory, Erasmus University Medical Center, Rotterdam; first published in Cell, March 2017

Last reviewed

2026-11-16

What is it good for?

FOXO4-DRI has no established use in people. It was designed to kill senescent cells — old, damaged cells that stop dividing but do not die — and in the 2017 mouse study it restored fitness, fur density and kidney function in fast-ageing and naturally old mice. No human trial is registered on ClinicalTrials.gov, and PubMed holds no record of it tagged as a clinical trial.

Illustration: A coiled molecular model representing a D-amino acid peptide, in white with green and copper accents.
Illustration

What it is

FOXO4-DRI is a synthetic peptide of 46 amino acids, every one of them a D-amino acid — the mirror-image form of the amino acids the body uses. It was designed to make senescent cells die. Senescent cells are cells that have stopped dividing after damage or with age but resist dying; they release inflammatory signals, and their build-up is linked to features of ageing in animals.

It was first described in Cell on 23 March 2017 by Baar and colleagues in the de Keizer laboratory at Erasmus University Medical Center in Rotterdam (PMID 28340339). The paper's methods section gives the full sequence, written in lower case to mark the D-form:

Property Value Source
Length 46 amino acids, all D-form Baar et al. 2017, methods
Sequence ltlrkepaseiaqsileaysqngwanrrsggkrppprrrqrrkkrg Baar et al. 2017, methods
Molecular weight 5,358.2 Baar et al. 2017, methods
Manufacturer in the study Pepscan, Lelystad, >95% purity Baar et al. 2017, methods
Human trials registered 0 ClinicalTrials.gov API, 2026-11-16

Two parts in one chain. The paper says the peptide was "designed as a fusion with HIV-TAT", a short sequence that lets cargo cross cell membranes. Reading the sequence, the last 13 residues — qpprrrqrrkkrg backwards — are that TAT segment in reversed order; the rest copies a region of FOXO4 the authors chose because it is conserved between humans and mice but differs from the related FOXO1 and FOXO3 (our reading of the sequence against the paper's description).

How it is meant to work

Inside a senescent cell, the protein FOXO4 holds the tumour-suppressor protein p53 in the nucleus, in a way that keeps the cell alive. FOXO4-DRI competes with FOXO4 for p53. In the 2017 experiments, the peptide bound p53 more strongly than FOXO4 did, p53 left the nucleus, and the senescent cells died by apoptosis, the cell's own shutdown programme. The paper also reports lower levels of p21Cip1, the cell-cycle brake that p53 controls — the protein whose name the nootropic research peptide p21 shares, though the two are unrelated. Treating senescent human fibroblasts with it reduced their numbers while normal cells were largely spared (Baar et al. 2017).

"Retro-inverso" is the design trick: using D-amino acids in reversed order can produce a peptide that presents its side chains much like the original but is not broken down by the body's enzymes. The paper cites this as the reason for the choice; it did not measure how long the peptide lasts in a person, because no person received it.

What the evidence shows

Evidence Who or what Finding Source
Cell studies Senescent human fibroblasts p53 left the nucleus; senescent cells died Baar 2017
Chemotherapy damage Mice given doxorubicin Peptide neutralised the drug's toxicity (body-weight and liver measures) Baar 2017
Fast-ageing mice XpdTTD/TTD mice Fitness, fur density and kidney function restored Baar 2017
Naturally aged mice 110+ weeks old Plasma urea and creatinine improved at 30 days Baar 2017
People — No registered trial, no published result ClinicalTrials.gov; PubMed

The mice received 5 mg per kg of body weight three times, every other day, by injection (Baar et al. 2017, figure legends). That figure is reported because it is the published animal protocol; there is no human dose on any record, because there is no human study.

Since 2017, the work that names FOXO4-DRI is mostly cell and animal research in other settings — for example a 2021 study using it on senescence-like fibroblasts after radiotherapy in lung-cancer models (JCI Insight, PMID 34877934). PubMed holds 19 records naming it, five of them reviews, and none tagged as a clinical or randomised trial (searched 2026-11-16).

What is not established: whether FOXO4-DRI is safe in people, whether it reaches human tissues, what it does to healthy cells over months, and whether any of the mouse effects occur in humans. An animal result is not a human result, and here there is no human result at all.

Where it stands

FOXO4-DRI is not approved by any regulator and has no registered human trial. It circulates as a research chemical on vendor sites that describe it as an anti-ageing peptide; those descriptions rest on the 2017 mouse study. Peptifact's FOXO4-DRI dosage page reports what vendors and forums cite. The library's overview of peptides sold for longevity sets it beside epitalon and the other compounds marketed on ageing. Anyone considering it is weighing a substance with no human safety record, a decision for a doctor.

A second research peptide organised around p53 is the p53-fragment peptide PNC-27, aimed at cancer cells rather than senescent ones, with a record that is equally pre-clinical.

Sources opened 2026-11-16: Baar et al., Cell 2017 (PMID 28340339, full text via PubMed Central PMC5556182); Krimpenfort and Berns, Cell 2017 commentary (PMID 28340347); Meng et al., JCI Insight 2021 (PMID 34877934); PubMed E-utilities and ClinicalTrials.gov API v2 searches.

What the research shows

Kills senescent cells selectively

Baar et al. 2017, Cell (PMID 28340339): in senescent human fibroblasts the peptide caused p53 to leave the nucleus and triggered cell death; healthy cells were largely spared

Restores fitness, fur and kidney function in old mice

Baar et al. 2017: fast-ageing XpdTTD/TTD mice and naturally aged mice, 5 mg/kg intravenously or intraperitoneally three times, every other day

Effects in people

None on record: ClinicalTrials.gov 0 studies; PubMed 0 records tagged clinical trial or randomised trial (2026-11-16)

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

Regulatory status

Not approved by any regulator. No application with FOXO4-DRI as an ingredient is on record in FDA's drug database.

Published record

PubMed: 19 records name FOXO4-DRI (5 reviews); 0 tagged as clinical trials. ClinicalTrials.gov: 0 studies (2026-11-16).

Where it is sold

As a research chemical by peptide vendors. A vendor listing is not a clinical record.

Frequently asked questions

What is FOXO4-DRI?

A laboratory-designed peptide of 46 D-amino acids, built to make senescent cells die. It was first published in Cell in 2017 and has been tested only in cells and mice.

What does DRI stand for?

D-retro-inverso. The peptide copies a stretch of the FOXO4 protein but uses D-amino acids, the mirror-image forms, in reversed order. The 2017 paper notes that such peptides can mimic the original and resist being broken down.

What is FOXO4-DRI said to be good for?

Vendor and forum pages describe it as an anti-ageing or senolytic peptide. The evidence behind that is the 2017 mouse study. No result in people has been published.

Has FOXO4-DRI been tested in humans?

Not in any registered trial. ClinicalTrials.gov returns no study for it, and PubMed has no record of it tagged as a clinical trial as of 16 November 2026.

Is FOXO4-DRI approved or legal to sell?

It is not approved by any regulator. It is sold online as a research chemical, which is not an approval for use in people.

Is FOXO4-DRI the same as FOXO4?

No. FOXO4 is a natural protein, a gene-regulating factor, that helps senescent cells survive. FOXO4-DRI is a short synthetic peptide designed to interfere with it.